Letters
Methylphenidate for moderate ADHD
Author’s reply to Timimi
BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6621 (Published 06 November 2013) Cite this as: BMJ 2013;347:f6621- Iain McClure, consultant child and adolescent psychiatrist1
- 1Royal Hospital for Sick Children, Edinburgh EH9 1LF, UK
- iain.mcclure{at}ed.ac.uk
Given the increasing costs of stimulant use,1 and the convincing argument about insufficient evidence that benefits outweigh harms in long term use for attention-deficit/hyperactivity disorder (ADHD) “of any severity,”2 3 isn’t it time that the Department of Health investigated the cost-benefit profile for such drug use? To decide on the best approach for our children, we need to balance the playing field. Government should match the considerable financial investment …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.